170 related articles for article (PubMed ID: 16525575)
1. Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis.
Hennan JK; Swillo RE; Morgan GA; Leik CE; Brooks JM; Shaw GD; Schaub RG; Crandall DL; Vlasuk GP
Thromb Haemost; 2006 Mar; 95(3):469-75. PubMed ID: 16525575
[TBL] [Abstract][Full Text] [Related]
2. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time.
Wadanoli M; Sako D; Shaw GD; Schaub RG; Wang Q; Tchernychev B; Xu J; Porter TJ; Huang Q
Thromb Haemost; 2007 Aug; 98(2):397-405. PubMed ID: 17721623
[TBL] [Abstract][Full Text] [Related]
3. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
Wang K; Zhou X; Huang Y; Khalil M; Wiktor D; van Giezen JJ; Penn MS
Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285
[TBL] [Abstract][Full Text] [Related]
4. The antithrombotic effect of melagatran in combination with clopidogrel and/or aspirin (carotid artery primary thrombosis study).
Hong TT; Huang J; Driscoll E; Lucchesi BR
J Cardiovasc Pharmacol; 2005 Oct; 46(4):526-33. PubMed ID: 16160608
[TBL] [Abstract][Full Text] [Related]
5. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis.
Lei X; Reheman A; Hou Y; Zhou H; Wang Y; Marshall AH; Liang C; Dai X; Li BX; Vanhoorelbeke K; Ni H
Thromb Haemost; 2014 Feb; 111(2):279-89. PubMed ID: 24172860
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
Rebello SS; Bentley RG; Morgan SR; Kasiewski CJ; Chu V; Perrone MH; Leadley RJ
Br J Pharmacol; 2001 Aug; 133(7):1190-8. PubMed ID: 11487531
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
8. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial.
Gurbel PA; Cummings CC; Bell CR; Alford AB; Meister AF; Serebruany VL;
Am Heart J; 2003 Feb; 145(2):239-47. PubMed ID: 12595840
[TBL] [Abstract][Full Text] [Related]
9. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Gurbel PA; Bliden KP; Zaman KA; Yoho JA; Hayes KM; Tantry US
Circulation; 2005 Mar; 111(9):1153-9. PubMed ID: 15738352
[TBL] [Abstract][Full Text] [Related]
10. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis.
Azzam K; Cissé-Thiam M; Drouet L
Thromb Haemost; 1996 Jan; 75(1):203-10. PubMed ID: 8713802
[TBL] [Abstract][Full Text] [Related]
11. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model.
Wåhlander K; Eriksson-Lepkowska M; Nyström P; Eriksson UG; Sarich TC; Badimon JJ; Kalies I; Elg M; Bylock A
Thromb Haemost; 2006 Mar; 95(3):447-53. PubMed ID: 16525572
[TBL] [Abstract][Full Text] [Related]
13. Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796.
Hennan JK; Hong TT; Willens DE; Driscoll EM; Giboulot TA; Lucchesi BR
Br J Pharmacol; 2002 Jul; 136(6):927-37. PubMed ID: 12110617
[TBL] [Abstract][Full Text] [Related]
14. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor.
Kageyama S; Yamamoto H; Nagano M; Arisaka H; Kayahara T; Yoshimoto R
Br J Pharmacol; 1997 Sep; 122(1):165-71. PubMed ID: 9298543
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of the interaction between von Willebrand factor and platelet GPIb/IX/V.
Gresele P; Momi S
Handb Exp Pharmacol; 2012; (210):287-309. PubMed ID: 22918736
[TBL] [Abstract][Full Text] [Related]
16. Anti-human vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs.
Kageyama S; Yamamoto H; Nakazawa H; Yoshimoto R
Thromb Res; 2001 Mar; 101(5):395-404. PubMed ID: 11297756
[TBL] [Abstract][Full Text] [Related]
17. Potent low dose platelet inhibitory effects of clopidogrel and aspirin on coronary thrombus formation in an animal model of acute unstable angina.
Bierbach B; Horstick G; Berg O; Heimann A; Münzel T; Vahl CF; Kempski O; Darius H
Thromb Haemost; 2006 Feb; 95(2):354-61. PubMed ID: 16502561
[TBL] [Abstract][Full Text] [Related]
18. Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis.
Kageyama S; Matsushita J; Yamamoto H
Eur J Pharmacol; 2002 May; 443(1-3):143-9. PubMed ID: 12044804
[TBL] [Abstract][Full Text] [Related]
19. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
[TBL] [Abstract][Full Text] [Related]
20. Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury.
Cook JJ; Glass JD; Sitko GR; Holahan MA; Stupienski RF; Wallace AA; Stump GL; Hand EL; Askew BC; Hartman GD; Gould RJ; Lynch JJ
Circulation; 1997 Aug; 96(3):949-58. PubMed ID: 9264506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
